Status
EARLY_EXP
Reversing chemotherapy resistance
Over 70,000 patients in the US are treated annually with chemotherapeutics such as Platinum, Etoposide, Irinotecan. 70% of these patients become resistant to treatment within two years.
Galatea is creating a novel medicine that reverses this chemo-resistance, potentially increasing the survival of patients with lung and ovarian cancer.